Late hepatitis B reactivation following direct-acting antiviral-based treatment of recurrent hepatitis C in an anti-HBc-positive liver transplant recipient.
Hepatology
; 67(2): 791-793, 2018 02.
Article
in En
| MEDLINE
| ID: mdl-28921620
ABSTRACT
Direct-acting antivirals (DAAs) have changed the landscape of hepatitis C virus (HCV) treatment, but chronic hepatitis C (CHC) remains a leading indication for liver transplantation (LT). Hepatitis B virus (HBV) reactivation has been reported in HBV-HCV-coinfected patients treated with DAAs. We report on a case of late HBV reactivation after DAA-based treatment of recurrent hepatitis C in an antibody against hepatitis B core antigen (anti-HBc)-positive LT recipient. (Hepatology 2018;67791-793).
Full text:
1
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Virus Activation
/
Hepatitis B virus
/
Liver Transplantation
/
Hepatitis C, Chronic
/
Hepatitis B Antibodies
/
Hepatitis B Core Antigens
Limits:
Humans
/
Male
/
Middle aged
Language:
En
Year:
2018
Type:
Article